

[REDACTED]

From: [REDACTED]
Sent: 05 February 2019 12:14
To: [REDACTED]
Cc: Woolley, Dr Jane
Subject: FW: Regulatory Update: France's FDA-Equivalent Agency Reissues Finasteride Warning

Hi [REDACTED]
This looks relatively in line with the DSU and seems to be a reminder due to increased ADRs. Have we had an uptick in reports of psychiatric disorders and persistent sexual dysfunction?

Letter here [REDACTED]
Our DSU here <https://www.gov.uk/drug-safety-update/finasteride-rare-reports-of-depression-and-suicidal-thoughts>

Best wishes
[REDACTED]

[REDACTED]

Vigilance and Risk Management of Medicines Division

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU

[REDACTED]

From: Raine, Dr June <June.Raine@mhra.gov.uk>
Sent: 04 February 2019 18:23
To: [REDACTED] Woolley, Dr Jane <Jane.Woolley@mhra.gov.uk>;
[REDACTED] Morgan, Sarah <Sarah.Morgan@mhra.gov.uk>
Subject: FW: Regulatory Update: France's FDA-Equivalent Agency Reissues Finasteride Warning

Dear All
FYI Interesting that ANSM has sent a DHPC letter on finasteride and the risk of psychiatric disorders and persistent sexual dysfunction.
I assume that the messages are equivalent to our DSU article?
June

From: [REDACTED]
Sent: 04 February 2019 13:10
To: Raine, Dr June <June.Raine@mhra.gov.uk>
Subject: FW: Regulatory Update: France's FDA-Equivalent Agency Reissues Finasteride Warning

[REDACTED]

Sent by proberts@pfsfoundation.org in collaboration with



Try it free today

This email has been scanned by the Symantec Email Security.cloud service.
For more information please visit <http://www.symanteccloud.com>
